Cargando…
Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma
BACKGROUND: A universally acknowledged cancer staging system considering all aspects of the T‐, N‐, and M‐classifications for middle ear squamous cell carcinoma (MESCC) remains absent, limiting the clinical management of MESCC patients. MATERIALS AND METHODS: A total of 214 MESCC patients were extra...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607269/ https://www.ncbi.nlm.nih.gov/pubmed/34559476 http://dx.doi.org/10.1002/cam4.4306 |
_version_ | 1784602531052126208 |
---|---|
author | Qiu, Ke Pang, Wendu Qiu, Jianqing Li, Junhong Cheng, Danni Rao, Yufang Dong, Yijun Mao, Minzi Liu, Qiurui Mu, Xiaosong Zhang, Wei Xu, Wei Ren, Jianjun Zhao, Yu |
author_facet | Qiu, Ke Pang, Wendu Qiu, Jianqing Li, Junhong Cheng, Danni Rao, Yufang Dong, Yijun Mao, Minzi Liu, Qiurui Mu, Xiaosong Zhang, Wei Xu, Wei Ren, Jianjun Zhao, Yu |
author_sort | Qiu, Ke |
collection | PubMed |
description | BACKGROUND: A universally acknowledged cancer staging system considering all aspects of the T‐, N‐, and M‐classifications for middle ear squamous cell carcinoma (MESCC) remains absent, limiting the clinical management of MESCC patients. MATERIALS AND METHODS: A total of 214 MESCC patients were extracted from the SEER (the Surveillance, Epidemiology, and End Results) database between 1973 and 2016. The relationships between patient’s characteristics and prognoses were analyzed by Kaplan–Meier and Cox proportional hazards regression models. Novel staging schemes for MESCC were designed by adjusted hazard ratio (AHR) modeling method according to the combinations of Stell’s T‐classification and the eighth AJCC N‐ and M‐classifications, of which performances were evaluated based on five criteria: hazard consistency, hazard discrimination, explained variation, likelihood difference, and balance. RESULTS: T‐classification was the most significant prognostic factor for MESCC patients in multivariable analysis (p = 0.021). The N‐ and M‐classifications also had obvious prognostic effect but were not statistically significant by multivariate analysis due to the limited metastasis events. Three novel staging schemes (AHR‐Ⅰ–Ⅲ models, different combination of T‐ and N‐classifications) and ST (solely derived from Stell’s T‐classification) were developed, among which the AHR‐Ⅰ staging scheme performed best. CONCLUSIONS: Tumor extension, quantified by Stell’s T‐classification, is the most significant prognostic factor for MESCC patients. However, our AHR‐Ⅰ staging scheme, a comprehensive staging scheme that integrating T‐, N‐, and M‐classifications, might be an optimal option for clinical practitioners to predict MESCC patients’ prognosis and make proper clinical decisions. |
format | Online Article Text |
id | pubmed-8607269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86072692021-11-29 Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma Qiu, Ke Pang, Wendu Qiu, Jianqing Li, Junhong Cheng, Danni Rao, Yufang Dong, Yijun Mao, Minzi Liu, Qiurui Mu, Xiaosong Zhang, Wei Xu, Wei Ren, Jianjun Zhao, Yu Cancer Med Clinical Cancer Research BACKGROUND: A universally acknowledged cancer staging system considering all aspects of the T‐, N‐, and M‐classifications for middle ear squamous cell carcinoma (MESCC) remains absent, limiting the clinical management of MESCC patients. MATERIALS AND METHODS: A total of 214 MESCC patients were extracted from the SEER (the Surveillance, Epidemiology, and End Results) database between 1973 and 2016. The relationships between patient’s characteristics and prognoses were analyzed by Kaplan–Meier and Cox proportional hazards regression models. Novel staging schemes for MESCC were designed by adjusted hazard ratio (AHR) modeling method according to the combinations of Stell’s T‐classification and the eighth AJCC N‐ and M‐classifications, of which performances were evaluated based on five criteria: hazard consistency, hazard discrimination, explained variation, likelihood difference, and balance. RESULTS: T‐classification was the most significant prognostic factor for MESCC patients in multivariable analysis (p = 0.021). The N‐ and M‐classifications also had obvious prognostic effect but were not statistically significant by multivariate analysis due to the limited metastasis events. Three novel staging schemes (AHR‐Ⅰ–Ⅲ models, different combination of T‐ and N‐classifications) and ST (solely derived from Stell’s T‐classification) were developed, among which the AHR‐Ⅰ staging scheme performed best. CONCLUSIONS: Tumor extension, quantified by Stell’s T‐classification, is the most significant prognostic factor for MESCC patients. However, our AHR‐Ⅰ staging scheme, a comprehensive staging scheme that integrating T‐, N‐, and M‐classifications, might be an optimal option for clinical practitioners to predict MESCC patients’ prognosis and make proper clinical decisions. John Wiley and Sons Inc. 2021-09-24 /pmc/articles/PMC8607269/ /pubmed/34559476 http://dx.doi.org/10.1002/cam4.4306 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Qiu, Ke Pang, Wendu Qiu, Jianqing Li, Junhong Cheng, Danni Rao, Yufang Dong, Yijun Mao, Minzi Liu, Qiurui Mu, Xiaosong Zhang, Wei Xu, Wei Ren, Jianjun Zhao, Yu Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma |
title | Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma |
title_full | Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma |
title_fullStr | Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma |
title_full_unstemmed | Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma |
title_short | Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma |
title_sort | evaluating the prognostic contributions of tnm classifications and building novel staging schemes for middle ear squamous cell carcinoma |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607269/ https://www.ncbi.nlm.nih.gov/pubmed/34559476 http://dx.doi.org/10.1002/cam4.4306 |
work_keys_str_mv | AT qiuke evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT pangwendu evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT qiujianqing evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT lijunhong evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT chengdanni evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT raoyufang evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT dongyijun evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT maominzi evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT liuqiurui evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT muxiaosong evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT zhangwei evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT xuwei evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT renjianjun evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma AT zhaoyu evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma |